Floatz logo

Jskn003

Non Small Cell Lung Cancer (NSCLC)

Jiangsu Alphamab Biopharmaceuticals Co., LtdPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Non Small Cell Lung Cancer (NSCLC) cohort.

Asset / SponsorPhaseRating
Bavituximab
Peregrine Pharmaceuticals
Phase 3BB
EXEMESTANE
Masonic Cancer Center, University of Minnesota
Phase 2B
ALCLOMETASONE
Pfizer
Phase 2B
Sovateltide
Spectrum Pharmaceuticals, Inc
Phase 2CCC
Jskn033
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2CCC

View all 13 →

Same molecule, other indications

Jskn003 is also rated in:

colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
primary peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
fallopian tube cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →